Literature DB >> 9369448

Biochemical basis of partial nephrogenic diabetes insipidus phenotypes.

H Sadeghi1, G L Robertson, D G Bichet, G Innamorati, M Birnbaumer.   

Abstract

Biochemical properties of mutant type 2 vasopressin receptors (V2Rs) causing a partial phenotype of nephrogenic diabetes insipidus were investigated in transiently transfected HEK 293 cells. Cell surface expression of the V2R was not altered by substituting Asp85 in the second transmembrane region by Asn as determined by saturation binding assays. Although the affinity of the mutant V2R for arginine vasopressin (AVP) was reduced only 6-fold, the response of adenylyl cyclase activity to AVP revealed a 50-fold right shift in EC50 and a decreased maximum response for the mutant V2R. These data indicated that replacement of Asp85 by Asn affected coupling of the receptor to Gs, a conclusion substantiated by a 20-fold decrease in the calculated coupling efficiency of this receptor. The Gly201Asp mutation in the second extracellular loop, also found associated with an NDI partial phenotype, decreased cell surface expression of the V2R with minor reduction in ligand-binding affinity and coupling efficiency to Gs. A pronounced difference was observed for this mutant V2R between the stimulation of adenylyl cyclase activity promoted by AVP and the V2 vasopressin receptor agonist deamino[Cys1,D-Arg8]-vasopressin, suggesting an involvement of Gly201 in the selectivity of the receptor for different ligands. These data demonstrated that while decreased ligand-binding affinity and decreased coupling to Gs are responsible for the attenuation of response to ligand in the Asp85Asn mutant V2R, cell surface expression of the V2R is the major factor reducing cellular responses to ligand for the Gly201Asp mutant V2R.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369448     DOI: 10.1210/mend.11.12.0017

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  13 in total

1.  V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.

Authors:  Kazuhiro Takahashi; Noriko Makita; Katsunori Manaka; Masataka Hisano; Yuko Akioka; Kenichiro Miura; Noriyuki Takubo; Atsuko Iida; Norishi Ueda; Makiko Hashimoto; Toshiro Fujita; Takashi Igarashi; Takashi Sekine; Taroh Iiri
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 2.  Genetic testing in renal disease.

Authors:  Detlef Bockenhauer; Alan J Medlar; Emma Ashton; Robert Kleta; Nick Lench
Journal:  Pediatr Nephrol       Date:  2011-05-27       Impact factor: 3.714

Review 3.  Familial forms of diabetes insipidus: clinical and molecular characteristics.

Authors:  Muriel Babey; Peter Kopp; Gary L Robertson
Journal:  Nat Rev Endocrinol       Date:  2011-07-05       Impact factor: 43.330

4.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Authors:  J P Morello; A Salahpour; A Laperrière; V Bernier; M F Arthus; M Lonergan; U Petäjä-Repo; S Angers; D Morin; D G Bichet; M Bouvier
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  Novel and recurrent variants in AVPR2 in 19 families with X-linked congenital nephrogenic diabetes insipidus.

Authors:  Shivani Joshi; Helene Kvistgaard; Konstantinos Kamperis; Mia Færch; Søren Hagstrøm; Niels Gregersen; Søren Rittig; Jane Hvarregaard Christensen
Journal:  Eur J Pediatr       Date:  2018-03-28       Impact factor: 3.183

Review 6.  Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.

Authors:  Detlef Bockenhauer; Daniel G Bichet
Journal:  Nat Rev Nephrol       Date:  2015-06-16       Impact factor: 28.314

7.  Analysis of a novel AVPR2 mutation in a family with nephrogenic diabetes insipidus.

Authors:  Sung-Dae Moon; Ju-Hee Kim; Joo-Yun Shim; Dong-Jun Lim; Bong-Yun Cha; Je-Ho Han
Journal:  Int J Clin Exp Med       Date:  2010-11-30

8.  Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.

Authors:  Noriko Makita; Tomohiko Sato; Yuki Yajima-Shoji; Junichiro Sato; Katsunori Manaka; Makiko Eda-Hashimoto; Masanori Ootaki; Naoki Matsumoto; Masaomi Nangaku; Taroh Iiri
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

9.  Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor.

Authors:  Karen Tan; Irina D Pogozheva; Giles S H Yeo; Dirk Hadaschik; Julia M Keogh; Carrie Haskell-Leuvano; Stephen O'Rahilly; Henry I Mosberg; I Sadaf Farooqi
Journal:  Endocrinology       Date:  2008-09-18       Impact factor: 4.736

10.  Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus.

Authors:  L S Barak; R H Oakley; S A Laporte; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.